Advertisement

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement

Aug

24

Today In Oncology

Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk

FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices

Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma

Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection

Advertisement

© 2026 HSP News Service, L.L.C.